Bergen, Norway 3 November 2023: Reference is made to stock exchange
notification 1 June 2022 with notification of trade of 25 000 shares by
primary insider Joacim Holter. Enclosed to the stock exchange notification was
a KRT 1500 form informing that the shares was planned to be transferred to
Joacim Holters children.

Today, Lifecare has received notification that Joacim Holter accordingly has
transferred a total of 24 999 shares to his closely related parties;

* Ingrid Holter (8 333 shares),
* Julie Holter, (8 333 shares),
* Fredrik Holter, (8 333 shares),

for a price of 3,00 NOK per share.

After the transfer, Joacim Holter holds a total of 292 998 shares in Lifecare
AS, as well as 1 331 355 shares through his fully owned investment company
Cimter AS, 1 331 355 shares.

About us
Lifecare AS is a clinical stage medical sensor company developing technology
for sensing and monitoring of various body analytes. Lifecare's main focus is
to bring the next generation of Continuous Glucose Monitoring ("CGM") systems
to market. Lifecare enables osmotic pressure as sensing principle, combined
with the ability to manipulate Nano-granular Tunnelling Resistive sensors
("NTR") on the sensor body for read-out of pressure variations. Lifecare's
sensor technology is referred to as "Sencell" and is suitable for identifying
and monitoring the occurrence of a wide range of analytes and molecules in the
human body.

Contacts
For further information, please contact:

Joacim Holter, CEO, Lifecare AS, joacim.holter@lifecare.no, +47 40 05 90 40

Asle Wingsternes, Head of Communications & Public Affairs,
asle.wingsternes@lifecare.no, +47 41 61 42 52

This information is information that Lifecare AS is obliged to make public
pursuant to the EU Market Abuse Regulation. The information was submitted for
publication, through the agency of the contact persons set out above, at
2023-11-03 18:15 CET.